Trastuzumab,Tucatinib,trastuzumab deruxtecan,zanidatamab
Seagen,daiichi sankyo,astrazeneca,jazz
['poziotinib', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'trastuzumab deruxtecan', 'zanidatamab', 'io,108,cl,01', 'rux,(-crux),(-trux)', 'tucatinib', 'colorectal', 'margetuximab', 'ca,022,i', 'pyrotinib', 'gi ', 'ca,022,1', 'rectal', 'zanida', 'kn,a 10', 'destiny,crc,01', 'ado,trastuzumab,emtansine', 'ibru', 'pertuzumab', 'destiny,crc,02', 'trastuzumab-deruxtecan', 'destiny,pantumor,2', 'loxo', 'effector ']
targeting the her2 pathway in gi cancers at #wcgic2023 amazing evolutions of targeted therapies for her2+ tumors t-dxt with pan-tumor activity t + tucatinib &amp; zanidatimab very promising we need to better understand the itme for io combinations 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology